Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Gensia Inc.

(GNSA)

Genta Inc.

(GNTA)

Alex. Brown analyst Kevin Tang downgraded GNSA to "neutral" from "buy" following the San Diego company's announcement that a setback in the scale-up of its Geomatrix nifedipine

Read the full 334 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE